ideasIdea
TCR therapeutics for non-HLA-A*02 patients
Today's T-cell-receptor drugs only work for people with one tissue type. Building versions for the other common types would roughly double who can be treated.
Tebentafusp and brenetafusp require HLA-A*02:01. Immunocore and others have preclinical ImmTACs against PRAME on HLA-A*24 and A*11, common in East Asian populations.
Hypothesis
PRAME-directed ImmTACs restricted to HLA-A*24:02 or A*11:01 achieve comparable activity and safety to the A*02 agent.
Rationale
Same antigen, same format; the only variable is the HLA context, which is a solved engineering problem in principle.
What would test it
Phase 1 dose escalation in HLA-A*24:02-positive melanoma in Japan and Korea, with ctDNA and OS follow-up mirroring IMCgp100-202.
Maturity
preclinical evidence